1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sam Chun Dang Pharm. Co., Ltd.

Sam Chun Dang Pharm. Co., Ltd.

KKRX:000250
199,200.00
KRW
-1,300.00
(-0.65%)
758.44EPS
1,886.58P/E
19.40TMarket Cap
Nov 12Next Earn
Sam Chun Dang Pharm. Co., Ltd.
KRX:000250
(Korea Stock Exchange)

Recent

price

199,200.00

P/E

ratio

1,886.58

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
3,860.06
4,018.94
3,945.7
5,416.69
5,972.37
6,473.55
7,138.85
7,506.74
7,473.18
8,712.66
7,775.69
7,578.07
8,050.31
8,591.73
9,158.75
9,956.24
10,566.91
Revenue per Share
250
293.49
69
452
595
570
422
585
409
488
-45
-750
265
-463
-474
226
439.42
Basic EPS, GAAP
375.23
467.64
-93.53
582.64
442.67
312.12
419.24
806.56
237.03
954.54
-398.32
-1,676.83
-1,510.18
64.87
-848.04
-2,138.73
-3,059.24
Free Cash Flow per Basic Share
99.87
100
49.68
50
48.46
122.51
98.02
96.38
96.57
96.51
96.32
43.87
43.96
39.28
38.65
199.79
- -
Dividend per Share
4,125.49
4,357.09
4,256.08
4,825.01
5,180.61
5,566.32
5,876.2
6,602.83
6,938.23
7,375.2
8,456.84
7,889
7,872.97
9,689.07
11,441.71
11,791.94
12,740.15
Book Value per Share
4,046.44
4,272.98
3,976.12
4,557.58
4,843.05
5,149.19
5,262.78
5,900.44
5,954.5
5,963.19
6,967.38
5,787.26
4,209.75
5,457.46
6,188.07
6,248.57
6,935.84
Tangible Book Value per Share
19
19
19
19
20
20
21
21
21
21
21
22
22
22
23
23
23
Basic Weighted Avg Shares
74,598
77,566
76,650
104,543
118,924
132,062
147,373
160,587
159,960
186,602
166,862
167,275
177,335
192,669
210,924
231,805
246,055
Sales/Revenue/Turnover
9.61
9.07
7.77
15.19
15.93
15.72
16.53
14.93
9.69
13.51
3.31
-9.14
6.89
4.96
1.25
3.65
5.38
Operating Margin (%)
4,147
1,922
2,319
4,112
4,082
4,220
5,358
6,250
6,303
6,491
6,685
6,741
7,651
8,430
9,029
10,993
11,712
Depreciation Expense
4,831
5,664
1,340
8,724
11,848
11,628
8,712
12,515
8,754
10,452
-966
-16,555
5,838
-10,383
-10,916
5,262
10,232
Net Income, GAAP
30.53
23.98
77.76
21
13.71
14.22
31.08
14.92
- -
- -
54.8
- -
0.98
- -
146.01
3.9
8.96
Effective Tax Rate (%)
6.48
7.3
1.75
8.34
9.96
8.81
5.91
7.79
5.47
5.6
-0.58
-9.9
3.29
-5.39
-5.18
2.27
4.16
Profit Margin (%)
49,400
51,891
32,342
56,968
67,624
77,232
90,457
107,508
103,853
117,287
142,869
114,901
119,590
105,949
149,112
135,187
130,314
Working Capital
- -
- -
6,441
1,374
- -
- -
- -
3,000
7,177
9,573
24,149
29,248
72,505
19,929
20,115
23,423
2,347
LT Debt
79,622
84,092
86,634
119,231
139,676
154,315
171,003
193,756
205,763
223,197
257,696
250,301
245,642
298,460
349,404
363,593
394,474
Total Equity
6.21
6.2
1.41
10.41
11.59
11.72
9.93
10.76
- -
- -
0.93
- -
3.88
- -
-0.32
1.91
2.83
Return on Invested Capital (%)
6.11
6.91
1.43
8.79
4.88
3.62
1.12
2.5
- -
- -
-3.44
- -
1.8
- -
-4.51
-0.14
0.87
Return on Capital (%)
6.19
6.92
1.61
9.95
11.93
10.58
7.28
9.39
6.04
6.82
-0.56
-9.18
3.36
-5.27
-4.49
1.94
3.65
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
47,286
46,408
46,377
LT Borrowings
21,153
21,032
- -
LT Finance Leases
2,655
2,391
2,347
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
5,012,073
5,442,236
19,404,789

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
221,319
241,759
240,295
Cash, Cash Equivalents & STI
117,100
129,058
110,369
Accounts Receivable, Net
38,548
45,577
54,312
Inventories
47,753
52,613
48,705
Total Current Liabilities
89,249
106,572
109,981
Payables & Accruals
- -
- -
- -
ST Debt
47,286
46,408
46,377
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.21%
7.58%
4.06%
Free Cash Flow
-84.33%
-213.82%
154.96%
Net Income, GAAP
95.68%
211.64%
-148.2%
Sales/Revenue/Turnover
6.05%
6.86%
9.9%
Total Cash Common Dividend
- -
- -
422.55%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,457
54,890
52,383
55,194
210,924
2025
50,618
56,900
58,024
66,263
231,805
2026
64,868
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
50
8
-48
-478.07
-474
2025
21
-143.44
110.62
238.49
226
2026
233.15
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
38.65
2025
204.26
- -
- -
- -
199.79
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sam Chun Dang Pharm. Co., Ltd manufactures and markets ethical drugs and over-the-counter pharmaceuticals primarily in South Korea, with exporting activities to international markets including the United States and Europe. Founded on December 29, 1943 and headquartered at 351 Hyoryeong-ro, Seocho-gu, Seoul, South Korea, the company specializes in therapeutic areas such as ophthalmology including its aflibercept biosimilar SCD411; cardiovascular; endocrinology; antibacterial; anti-fungal; antiviral; respiratory including stimulants and pneumonia diagnostic devices; anti-inflammatory; antihistamine; musculoskeletal; vitamins; and gastro-intestinal products. It employs approximately 392 to 410 people and operates production facilities supporting its domestic sales network and global exports. Recent developments include receiving KRW 29.5419 billion in funding from investors such as Pureun Investment Inc. and Shinhan Investment & Securities Co., Ltd; expansion of SCD411 supply and sales contracts to additional European countries including France in 2025 alongside prior deals covering the United States and seven other nations for this Eylea biosimilar; and securing European Medicines Agency marketing authorization for its aflibercept biosimilar in August 2025, positioning it as a potential first-to-market pre-filled syringe option in the region.